SCHEMBL19424302

SCHEMBL19424302

CCN(CC)C[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(Cl)cc5)CCCC4)CC3)cc2)cc1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCL2 P10415 11/20 0.61
▸ BAD Q92934 4/20 0.60
▸ BCL2L1 Q07817 12/20 0.60
▸ BCL2L2 Q92843 3/20 0.58
▸ BCL2L11 O43521 2/20 0.58
▸ MCL1 Q07820 2/20 0.58
▸ ASPH Q12797 2/20 0.58
▸ CYP2C9 P11712 1/20 0.58
▸ MDM4 O15151 1/20 0.56
▸ TP53 P04637 1/20 0.56
▸ BID P55957 1/20 0.56
▸ BAX Q07812 1/20 0.56
▸ BECN1 Q14457 1/20 0.56
▸ BAK1 Q16611 1/20 0.56
▸ BBC3 Q9BXH1 1/20 0.56
▸ HDAC3 O15379 3/20 0.53
▸ HDAC4 P56524 3/20 0.53
▸ HDAC1 Q13547 3/20 0.53
▸ HDAC7 Q8WUI4 3/20 0.53
▸ HDAC2 Q92769 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7872304 0.92 BCL2L1 (0.67) BCL2BADBCL2L1BCL2L2BCL2L11
SCHEMBL1540817 0.92 BCL2 (0.73) BCL2BADBCL2L1BCL2L2BCL2L11
SCHEMBL27808072 0.92 BCL2 (0.73) BCL2BADBCL2L1BCL2L2BCL2L11
SCHEMBL2026815 0.92 BCL2L1 (0.69) BCL2BADBCL2L1BCL2L2BCL2L11
SCHEMBL14463310 0.91 BCL2 (0.64) BCL2BADBCL2L1BCL2L2BCL2L11
SCHEMBL19425083 0.90 BCL2 (0.73) BCL2BADBCL2L1BCL2L2BCL2L11
SCHEMBL19424355 0.90 BCL2 (0.74) BCL2BADBCL2L1BCL2L2BCL2L11
SCHEMBL19424240 0.89 BCL2 (0.72) BCL2BADBCL2L1BCL2L2BCL2L11
SCHEMBL19424331 0.89 BCL2 (0.65) BCL2BADBCL2L1BCL2L2BCL2L11
SCHEMBL19424263 0.89 BCL2L1 (0.72) BCL2BADBCL2L1BCL2L2BCL2L11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease UNITY BIOTECHNOLOGY, INC. (US) 2019-02-05 — — US disclosed
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES TP53, NQO1, SHMT2 BCL2 520/4885BAD 421/4885BCL2L1 953/4885
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease TP53, CDKN1A, GLA BCL2 132/4885BAD 16/4885BCL2L1 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback